ClinicalTrials.gg
CompletedNCT05464420Updated Sep 24, 2024Results posted

A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4)

A Phase 3 interventional study of V116 and PPSV23 in Pneumococcal Disease, sponsored by Merck Sharp & Dohme LLC. Completed at 72 sites in 8 countries. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-24.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,162
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections — 1 open to participants now, 2 under way, 2 of them phase 3. Pneumococcal 21-Valent Conjugate Vaccine · Pneumococcal Infections.

Enrollment
3rd of 10
2,162 · median 1,075
Started
2022
with 3 others
Phase 3
9 of 10
1 open now
Registered
4th of 10
by date
Lead sponsor
8 of 10
Merck Sharp & Dohme LLC

Among the 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections, this one is the 3rd largest by enrollment, is one of 4 that started in 2022, is one of 9 in phase 3, and was the 4th registered.

Pneumococcal Infections

299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

1 of the 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections is open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About Pneumococcal 21-Valent Conjugate Vaccine

Pneumococcal 21-Valent Conjugate Vaccine: first FDA approval 2024 (CAPVAXIVE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 49 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections, or all of them as a file.
02

Study summary

This study will evaluate the safety, tolerability, and immunogenicity of a pneumococcal 21-valent conjugate vaccine (V116) in pneumococcal vaccine-naïve adults 18 to 49 years of age.

The primary study hypothesis is that all 3 lots of V116 are equivalent as assessed by the serotype-specific opsonophagocytic activity (OPA) Geometric Mean Titers (GMTs) at 30 days postvaccination for all serotypes included in V116.

03

Conditions studied

  • Pneumococcal Disease
04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

The key inclusion and exclusion criteria include but are not limited to the following:

Inclusion criteria

Inclusion Criteria:

  • Has underlying chronic conditions but assessed to be stable as per investigator
  • Has ability to complete electronic Vaccine Report Card (eVRC) data collection without assistance as per investigator

Exclusion criteria

Exclusion Criteria:

  • Has a history of invasive pneumococcal disease (IPD) or other culture-positive pneumococcal disease ≤3 years before Visit 1 (Day 1)
  • Has a known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of disease
  • Has a coagulation disorder contraindicating intramuscular vaccination
  • Has a recent illness with fever
  • Has a known that is progressing or has required active treatment \<3 years before enrollment
  • Is expected to receive any pneumococcal vaccine during the study outside of the protocol
  • Has received systemic for ≥14 consecutive days and has not completed treatment ≥14 days before receipt of study vaccine
  • Is currently receiving therapy, including chemotherapeutic agents or other immunotherapies/immunomodulators used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease
  • Has received any non- ≤14 days before receipt of study vaccine or is scheduled to receive any non-live vaccine ≤30 days after receipt of study vaccine
  • Has received any live vaccine ≤30 days before receipt of study vaccine or is scheduled to receive any live vaccine ≤30 days after receipt of study vaccine
  • Has received a blood transfusion or blood products, including immunoglobulins ≤6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product ≤30 days after receipt of study vaccine
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
2,162 participants (actual)

Study arms

  • Experimental
    V116 Lot 1

    Participants will receive a single 0.5 mL intramuscular (IM) dose of V116 Lot 1 on Day 1.

    Biological: V116

  • Experimental
    V116 Lot 2

    Participants will receive a single 0.5 mL IM dose of V116 Lot 2 on Day 1.

    Biological: V116

  • Experimental
    V116 Lot 3

    Participants will receive a single 0.5 mL IM dose of V116 Lot 3 on Day 1.

    Biological: V116

  • Active comparator
    PPSV23

    Participants will receive a single 0.5 mL IM dose of PPSV23 on Day 1.

    Biological: PPSV23

Interventions

  • BiologicalV116

    Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution

    Also known as: Pneumococcal 21-valent Conjugate Vaccine

  • BiologicalPPSV23

    Drug page: 23-valent pneumococcal capsular polysaccharide vaccine

    Pneumococcal 23-valent conjugate vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution

    Also known as: PNEUMOVAX™23

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Solicited Injection-site Adverse Events (AEs) Following Vaccination With Separate V116 Lots

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection-site AEs included pain/tenderness, redness/erythema, and swelling. Per protocol, the PPSV23 treatment group was not included as it was not analyzed with the individual lots of V116.

    Time frame: Up to 5 days

  2. Percentage of Participants With Solicited Injection-site AEs Following Vaccination: Combined Lots of V116 or PPSV23

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection-site AEs included pain/tenderness, redness/erythema, and swelling. Per the statistical analysis plan, no within group method of dispersion (MOD) were planned or calculated.

    Time frame: Up to 5 days

  3. Percentage of Participants With Solicited Systemic AEs Following Vaccination With Separate V116 Lots

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited systemic AEs included headache, muscle aches/myalgia, tiredness/fatigue, and pyrexia. Per protocol, the PPSV23 treatment group was not included as it was not analyzed with the individual lots of V116.

    Time frame: Up to 5 days

  4. Percentage of Participants With Solicited Systemic AEs Following Vaccination: Combined Lots of V116 or PPSV23

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited systemic AEs included headache, muscle aches/myalgia, tiredness/fatigue, and pyrexia. Per the statistical analysis plan, no within group method of dispersion (MOD) were planned or calculated.

    Time frame: Up to 5 days

  5. Percentage of Participants With Vaccine-related Serious Adverse Events (SAEs) Following Vaccination With Separate V116 Lots

    An SAE was any untoward medical occurrence that, at any dose, resulted in death, was life threatening, required inpatient hospitalization or prolonged existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was another important medical event. SAEs that were reported to be at least possibly related by the investigator to study vaccination were reported. Per protocol, the PPSV23 treatment group was not included as it was not analyzed with the individual lots of V116.

    Time frame: Up to 194 days

  6. Percentage of Participants With Vaccine-related SAEs Following Vaccination: Combined Lots of V116 or PPSV23

    An SAE was any untoward medical occurrence that, at any dose, resulted in death, was life threatening, required inpatient hospitalization or prolonged existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was another important medical event. SAEs that were reported to be at least possibly related by the investigator to study vaccination were reported. Per the statistical analysis plan, no within group MOD were planned or calculated.

    Time frame: Up to 194 days

  7. Geometric Mean Titers (GMTs) of Serotype-specific Opsonophagocytic Activity (OPA) for All Serotypes in V116 Following Vaccination With Separate V116 Lots

    Serotype-specific OPA titers for all serotypes in V116 following vaccination were determined using multiplex opsonophagocytic assay (MOPA). Serotype-specific OPA GMTs and GMT ratios with 95% confidence intervals (CIs) were calculated using a constrained longitudinal data analysis (cLDA) model. Per protocol, within-group CIs were not calculated and the PPSV23 treatment group was not included as it was not analyzed with the individual lots of V116.

    Time frame: Day 30

Secondary outcomes

  1. GMTs of Serotype-specific OPA for All Serotypes in V116 Following Vaccination: Combined Lots of V116 or PPSV23

    Serotype-specific OPA titers for all serotypes in V116 following vaccination were determined using MOPA. Serotype-specific OPA GMTs and GMT ratios with 95% CI were calculated using a constrained longitudinal data analysis (cLDA) model. Per protocol, within-group CIs were not calculated.

    Time frame: Day 30

  2. Geometric Mean Concentrations (GMCs) of Serotype-specific Immunoglobulin G (IgG) for All Serotypes in V116 Following Vaccination With Separate V116 Lots

    Serotype-specific IgG concentrations for all serotypes in V116 following vaccination were determined using pneumococcal electrochemiluminescence (PnECL). Serotype-specific pneumococcal IgG GMCs and GMC ratios with 95% confidence intervals were calculated using a cLDA model. Per protocol, within-group CIs were not calculated and the PPSV23 treatment group was not included as it was not analyzed with the individual lots of V116.

    Time frame: Day 30

  3. GMCs of Serotype-specific IgG for All Serotypes in V116 Following Vaccination: Combined Lots of V116 or PPSV23

    Serotype-specific IgG concentrations for all serotypes in V116 following vaccination were determined using PnECL. Serotype-specific pneumococcal IgG GMCs and GMC ratios with 95% confidence intervals were calculated using a cLDA model. Per protocol, within-group CIs were not calculated.

    Time frame: Day 30

  4. Geometric Mean Fold Rise (GMFR) in Serotype-specific OPA for All Serotypes in V116 Following Vaccination With Separate V116 Lots

    Serotype-specific OPA GMFR for all serotypes in V116 following vaccination were determined using MOPA. The GMFR of each pneumococcal serotype was calculated as Day 30 GMT/Day 1 GMT. The 95% CIs were calculated based on based on the t-distribution. Per protocol, the PPSV23 treatment group was not included as it was not analyzed with the individual lots of V116.

    Time frame: Baseline (Day 1) and Day 30

  5. Percentage of Participants With ≥4-fold Rise in Serotype-specific OPA for All Serotypes in V116 Following Vaccination With Separate V116 Lots

    Serotype-specific OPA titer were determined using MOPA. The percentage of participants with a ≥4-fold rise in serotype-specific OPA for all serotypes in V116 following vaccination were reported. The 95% CIs were calculated based on the exact binomial method proposed by Clopper and Pearson. Per protocol, the PPSV23 treatment group was not included as it was not analyzed with the individual lots of V116.

    Time frame: Baseline (Day 1) and Day 30

  6. GMFR in Serotype-specific IgG for All Serotypes in V116 Following Vaccination With Separate V116 Lots

    Serotype-specific IgG GMFR for all serotypes in V116 following vaccination were determined using PnECL. The GMFR for each pneumococcal IgG serotype was calculated as Day 30 GMC/Day 1 GMC. The 95% CIs were calculated based on the t-distribution. Per protocol, the PPSV23 treatment group was not included as it was not analyzed with the individual lots of V116.

    Time frame: Baseline (Day 1) and Day 30

  7. Percentage of Participants With ≥4-fold Rise in Serotype-specific IgG for All Serotypes in V116 Following Vaccination With Separate V116 Lots

    Serotype-specific IgG concentrations were determined using PnECL. The percentage of participants with a ≥4-fold rise in serotype-specific IgG for all serotypes in V116 were reported. The 95% CIs were calculated based on the exact binomial method proposed by Clopper and Pearson. Per protocol, the PPSV23 treatment group was not included as it was not analyzed with the individual lots of V116.

    Time frame: Baseline (Day 1) and Day 30

  8. GMTs of Serotype-specific OPA for Cross-reactive Serotypes Following Vaccination With Separate V116 Lots

    Serotype-specific OPA titers for cross-reactive serotypes (6A, 6C, 15B, and 15C) were determined using MOPA. The 95% CIs for serotype-specific OPA GMTs were calculated based on based on the t-distribution. Per protocol, the PPSV23 treatment group was not included as it was not analyzed with the individual lots of V116.

    Time frame: Day 30

07

Results

Posted May 24, 2024

Participant flow

Healthy pneumococcal vaccine-naïve adults between 18 and 49 years of age were enrolled in this study.

Participant flow — Overall Study
MilestoneV116 Lot 1V116 Lot 2V116 Lot 3PPSV23
Started541540541540
Vaccinated539538540540
Safety analysis population539536541541
Completed521520525526
Not completed20201614
Withdrew: Death0001
Withdrew: Lost to follow-up16111111
Withdrew: Randomized in error without study treatment0100
Withdrew: Withdrawal by subject4831
Withdrew: Protocol violation0011
Withdrew: Unable to adhere to study schedule0010

Outcome measures

PrimaryPercentage of Participants With Solicited Injection-site Adverse Events (AEs) Following Vaccination With Separate V116 Lots

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection-site AEs included pain/tenderness, redness/erythema, and swelling. Per protocol, the PPSV23 treatment group was not included as it was not analyzed with the individual lots of V116.

Time frame:
Up to 5 days
Reported as:
Number · Percentage of Participants
Percentage of Participants With Solicited Injection-site Adverse Events (AEs) Following Vaccination With Separate V116 Lots
Percentage of ParticipantsV116 Lot 1V116 Lot 2V116 Lot 3PPSV23
Injection site erythema13.4 (10.6 to 16.5)14.2 (11.3 to 17.4)13.1 (10.4 to 16.3)—
Injection site pain72.9 (68.9 to 76.6)72.9 (69.0 to 76.7)73.9 (70.0 to 77.6)—
Injection site swelling12.4 (9.8 to 15.5)15.3 (12.4 to 18.6)11.8 (9.2 to 14.9)—
PrimaryPercentage of Participants With Solicited Injection-site AEs Following Vaccination: Combined Lots of V116 or PPSV23

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection-site AEs included pain/tenderness, redness/erythema, and swelling. Per the statistical analysis plan, no within group method of dispersion (MOD) were planned or calculated.

Time frame:
Up to 5 days
Reported as:
Number · Percentage of Participants
Percentage of Participants With Solicited Injection-site AEs Following Vaccination: Combined Lots of V116 or PPSV23
Percentage of ParticipantsV116 Combined Lots 1, 2, and 3PPSV23
Injection site erythema13.67.6
Injection site pain73.360.6
Injection site swelling13.27.6
Statistical analysis
  • V116 Combined Lots 1, 2, and 3 vs PPSV23 · Estimated difference in percentage: 6.0 · 95% CI 3.0 to 8.6
  • V116 Combined Lots 1, 2, and 3 vs PPSV23 · Estimated difference in percentage: 12.6 · 95% CI 8.0 to 17.3
  • V116 Combined Lots 1, 2, and 3 vs PPSV23 · Estimated difference in percentage: 5.6 · 95% CI 2.6 to 8.2
PrimaryPercentage of Participants With Solicited Systemic AEs Following Vaccination With Separate V116 Lots

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited systemic AEs included headache, muscle aches/myalgia, tiredness/fatigue, and pyrexia. Per protocol, the PPSV23 treatment group was not included as it was not analyzed with the individual lots of V116.

Time frame:
Up to 5 days
Reported as:
Number · Percentage of Participants
Percentage of Participants With Solicited Systemic AEs Following Vaccination With Separate V116 Lots
Percentage of ParticipantsV116 Lot 1V116 Lot 2V116 Lot 3PPSV23
Fatigue38.0 (33.9 to 42.3)34.0 (30.0 to 38.1)34.4 (30.4 to 38.6)—
Headache28.0 (24.3 to 32.0)26.1 (22.4 to 30.1)27.5 (23.8 to 31.5)—
Myalgia18.2 (15.0 to 21.7)13.6 (10.8 to 16.8)17.2 (14.1 to 20.6)—
Pyrexia3.2 (1.8 to 5.0)2.2 (1.2 to 3.9)3.5 (2.1 to 5.4)—
PrimaryPercentage of Participants With Solicited Systemic AEs Following Vaccination: Combined Lots of V116 or PPSV23

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited systemic AEs included headache, muscle aches/myalgia, tiredness/fatigue, and pyrexia. Per the statistical analysis plan, no within group method of dispersion (MOD) were planned or calculated.

Time frame:
Up to 5 days
Reported as:
Number · Percentage of Participants
Percentage of Participants With Solicited Systemic AEs Following Vaccination: Combined Lots of V116 or PPSV23
Percentage of ParticipantsV116 Combined Lots 1, 2, and 3PPSV23
Fatigue35.534.0
Headache27.221.4
Myalgia16.38.7
Pyrexia3.02.2
Statistical analysis
  • V116 Combined Lots 1, 2, and 3 vs PPSV23 · Estimated difference in percentage: 1.4 · 95% CI -3.2 to 6.0
  • V116 Combined Lots 1, 2, and 3 vs PPSV23 · Estimated difference in percentage: 5.8 · 95% CI 1.6 to 9.7
  • V116 Combined Lots 1, 2, and 3 vs PPSV23 · Estimated difference in percentage: 7.6 · 95% CI 4.5 to 10.5
  • V116 Combined Lots 1, 2, and 3 vs PPSV23 · Estimated difference in percentage: 0.8 · 95% CI -1.0 to 2.1
PrimaryPercentage of Participants With Vaccine-related Serious Adverse Events (SAEs) Following Vaccination With Separate V116 Lots

An SAE was any untoward medical occurrence that, at any dose, resulted in death, was life threatening, required inpatient hospitalization or prolonged existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was another important medical event. SAEs that were reported to be at least possibly related by the investigator to study vaccination were reported. Per protocol, the PPSV23 treatment group was not included as it was not analyzed with the individual lots of V116.

Time frame:
Up to 194 days
Reported as:
Number · Percentage of Participants
Percentage of Participants With Vaccine-related Serious Adverse Events (SAEs) Following Vaccination With Separate V116 Lots
Percentage of ParticipantsV116 Lot 1V116 Lot 2V116 Lot 3PPSV23
Percentage of Participants With Vaccine-related Serious Adverse Events (SAEs) Following Vaccination With Separate V116 Lots0.0 (0.0 to 0.7)0.0 (0.0 to 0.7)0.0 (0.0 to 0.7)—
PrimaryPercentage of Participants With Vaccine-related SAEs Following Vaccination: Combined Lots of V116 or PPSV23

An SAE was any untoward medical occurrence that, at any dose, resulted in death, was life threatening, required inpatient hospitalization or prolonged existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was another important medical event. SAEs that were reported to be at least possibly related by the investigator to study vaccination were reported. Per the statistical analysis plan, no within group MOD were planned or calculated.

Time frame:
Up to 194 days
Reported as:
Number · Percentage of Participants
Percentage of Participants With Vaccine-related SAEs Following Vaccination: Combined Lots of V116 or PPSV23
Percentage of ParticipantsV116 Combined Lots 1, 2, and 3PPSV23
Percentage of Participants With Vaccine-related SAEs Following Vaccination: Combined Lots of V116 or PPSV230.00.0
Statistical analysis
  • V116 Combined Lots 1, 2, and 3 vs PPSV23 · Estimated difference in percentage: 0.0 · 95% CI -0.7 to 0.2
PrimaryGeometric Mean Titers (GMTs) of Serotype-specific Opsonophagocytic Activity (OPA) for All Serotypes in V116 Following Vaccination With Separate V116 Lots

Serotype-specific OPA titers for all serotypes in V116 following vaccination were determined using multiplex opsonophagocytic assay (MOPA). Serotype-specific OPA GMTs and GMT ratios with 95% confidence intervals (CIs) were calculated using a constrained longitudinal data analysis (cLDA) model. Per protocol, within-group CIs were not calculated and the PPSV23 treatment group was not included as it was not analyzed with the individual lots of V116.

Time frame:
Day 30
Reported as:
Geometric mean · Titers
Geometric Mean Titers (GMTs) of Serotype-specific Opsonophagocytic Activity (OPA) for All Serotypes in V116 Following Vaccination With Separate V116 Lots
TitersV116 Lot 1V116 Lot 2V116 Lot 3PPSV23
Serotype 3327.2 (NA to NA)299.0 (NA to NA)318.8 (NA to NA)—
Serotype 6A6901.9 (NA to NA)6014.9 (NA to NA)6641.2 (NA to NA)—
Serotype 7F7219.8 (NA to NA)6201.8 (NA to NA)6657.0 (NA to NA)—
Serotype 83935.5 (NA to NA)3812.8 (NA to NA)3765.8 (NA to NA)—
Serotype 9N18747.4 (NA to NA)17201.6 (NA to NA)18557.8 (NA to NA)—
Serotype 10A7570.2 (NA to NA)7796.9 (NA to NA)7330.4 (NA to NA)—
Serotype 11A6396.0 (NA to NA)6630.9 (NA to NA)6374.5 (NA to NA)—
Serotype 12F7478.5 (NA to NA)6803.0 (NA to NA)7329.9 (NA to NA)—
Serotype 15A10698.5 (NA to NA)10253.9 (NA to NA)10692.3 (NA to NA)—
Serotype 15C13133.8 (NA to NA)11441.3 (NA to NA)11177.1 (NA to NA)—
Serotype 16F9239.1 (NA to NA)9550.8 (NA to NA)9530.1 (NA to NA)—
Serotype 17F17185.3 (NA to NA)17718.6 (NA to NA)16886.7 (NA to NA)—
Serotype 19A3187.1 (NA to NA)3123.3 (NA to NA)3368.0 (NA to NA)—
Serotype 20A16339.3 (NA to NA)16676.2 (NA to NA)15302.4 (NA to NA)—
Serotype 22F11638.5 (NA to NA)10614.3 (NA to NA)11346.7 (NA to NA)—
Serotype 23A8437.4 (NA to NA)8459.8 (NA to NA)8322.8 (NA to NA)—
Serotype 23B2964.1 (NA to NA)2435.5 (NA to NA)3035.5 (NA to NA)—
Serotype 24F4861.3 (NA to NA)4783.4 (NA to NA)4758.8 (NA to NA)—
Serotype 319052.0 (NA to NA)8831.6 (NA to NA)8870.7 (NA to NA)—
Serotype 33F37994.1 (NA to NA)34227.3 (NA to NA)35182.5 (NA to NA)—
Serotype 35B12971.8 (NA to NA)12586.6 (NA to NA)12494.5 (NA to NA)—
Statistical analysis
  • V116 Lot 1 vs V116 Lot 2 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 1.09 · 95% CI 0.96 to 1.24V116 Lot 1/V116 Lot 2
  • V116 Lot 1 vs V116 Lot 3 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 1.03 · 95% CI 0.90 to 1.17V116 Lot 1/ V116 Lot 3
  • V116 Lot 2 vs V116 Lot 3 · cLDA Model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 0.94 · 95% CI 0.83 to 1.06V116 Lot 2/ V116 Lot 3
  • V116 Lot 1 vs V116 Lot 2 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 1.15 · 95% CI 0.97 to 1.35V116 Lot 1/V116 Lot 2
  • V116 Lot 1 vs V116 Lot 3 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 1.04 · 95% CI 0.88 to 1.22V116 Lot 1/V116 Lot 3
  • V116 Lot 2 vs V116 Lot 3 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 0.91 · 95% CI 0.77 to 1.06V116 Lot 2/V116 Lot 3
  • V116 Lot 1 vs V116 Lot 2 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 1.16 · 95% CI 1.01 to 1.34V116 Lot 1/V116 Lot 2
  • V116 Lot 1 vs V116 Lot 3 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 1.08 · 95% CI 0.94 to 1.25V116 Lot 1/V116 Lot 3
  • V116 Lot 2 vs V116 Lot 3 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 0.93 · 95% CI 0.81 to 1.07V116 Lot 2/V116 Lot 3
  • V116 Lot 1 vs V116 Lot 2 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 1.03 · 95% CI 0.92 to 1.16V116 Lot 1/V116 Lot 2
  • V116 Lot 1 vs V116 Lot 3 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 1.05 · 95% CI 0.93 to 1.18V116 Lot 1/ V116 Lot 3
  • V116 Lot 2 vs V116 Lot 3 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 1.01 · 95% CI 0.90 to 1.14V116 Lot 2/ V116 Lot 3
  • V116 Lot 1 vs V116 Lot 2 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 1.09 · 95% CI 0.94 to 1.26V116 Lot 1/V116 Lot 2
  • V116 Lot 1 vs V116 Lot 3 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 1.01 · 95% CI 0.87 to 1.17V116 Lot 1/V116 Lot 3
  • V116 Lot 2 vs V116 Lot 3 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 0.93 · 95% CI 0.80 to 1.07V116 Lot 2/V116 Lot 3
  • V116 Lot 1 vs V116 Lot 2 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 0.97 · 95% CI 0.85 to 1.11V116 Lot 1/V116 Lot 2
  • V116 Lot 1 vs V116 Lot 3 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 1.03 · 95% CI 0.91 to 1.18V116 Lot 1/V116 Lot 3
  • V116 Lot 2 vs V116 Lot 3 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 1.06 · 95% CI 0.93 to 1.21V116 Lot 2/V116 Lot 3
  • V116 Lot 1 vs V116 Lot 2 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 0.96 · 95% CI 0.84 to 1.11V116 Lot 1/V116 Lot 2
  • V116 Lot 1 vs V116 Lot 3 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 1.00 · 95% CI 0.87 to 1.16V116 Lot 1/V116 Lot 3
  • V116 Lot 2 vs V116 Lot 3 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 1.04 · 95% CI 0.90 to 1.20V116 Lot 2/V116 Lot 3
  • V116 Lot 1 vs V116 Lot 2 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 1.10 · 95% CI 0.96 to 1.26V116 Lot 1/V116 Lot 2
  • V116 Lot 1 vs V116 Lot 3 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 1.02 · 95% CI 0.89 to 1.17V116 Lot 1/V116 Lot 3
  • V116 Lot 2 vs V116 Lot 3 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 0.93 · 95% CI 0.81 to 1.07V116 Lot 2/V116 Lot 3
  • V116 Lot 1 vs V116 Lot 2 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 1.04 · 95% CI 0.89 to 1.22V116 Lot 1/V116 Lot 2
  • V116 Lot 1 vs V116 Lot 3 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 1.00 · 95% CI 0.86 to 1.17V116 Lot 1/V116 Lot 3
  • V116 Lot 2 vs V116 Lot 3 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 0.96 · 95% CI 0.82 to 1.12V116 Lot 2/V116 Lot 3
  • V116 Lot 1 vs V116 Lot 2 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 1.15 · 95% CI 0.95 to 1.38V116 Lot 1/V116 Lot 2
  • V116 Lot 1 vs V116 Lot 3 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 1.18 · 95% CI 0.97 to 1.42V116 Lot 1/V116 Lot 3
  • V116 Lot 2 vs V116 Lot 3 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 1.02 · 95% CI 0.85 to 1.23V116 Lot 2/V116 Lot 3
  • V116 Lot 1 vs V116 Lot 2 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 0.97 · 95% CI 0.84 to 1.11V116 Lot 1/V116 Lot 2
  • V116 Lot 1 vs V116 Lot 3 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 0.97 · 95% CI 0.84 to 1.11V116 Lot 1/V116 Lot 3
  • V116 Lot 2 vs V116 Lot 3 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 1.00 · 95% CI 0.87 to 1.15V116 Lot 2/V116 Lot 3
  • V116 Lot 1 vs V116 Lot 2 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 0.97 · 95% CI 0.85 to 1.11V116 Lot 1/V116 Lot 2
  • V116 Lot 1 vs V116 Lot 3 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 1.02 · 95% CI 0.89 to 1.17V116 Lot 1/V116 Lot 3
  • V116 Lot 2 vs V116 Lot 3 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 1.05 · 95% CI 0.92 to 1.20V116 Lot 2/V116 Lot 3
  • V116 Lot 1 vs V116 Lot 2 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 1.02 · 95% CI 0.91 to 1.15V116 Lot 1/V116 Lot 2
  • V116 Lot 1 vs V116 Lot 3 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 0.95 · 95% CI 0.84 to 1.07V116 Lot 1/V116 Lot 3
  • V116 Lot 2 vs V116 Lot 3 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 0.93 · 95% CI 0.82 to 1.04V116 Lot 2/V116 Lot 3
  • V116 Lot 1 vs V116 Lot 2 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 0.98 · 95% CI 0.84 to 1.14V116 Lot 1/V116 Lot 2
  • V116 Lot 1 vs V116 Lot 3 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 1.07 · 95% CI 0.92 to 1.24V116 Lot 1/V116 Lot 3
  • V116 Lot 2 vs V116 Lot 3 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 1.09 · 95% CI 0.94 to 1.27V116 Lot 2/V116 Lot 3
  • V116 Lot 1 vs V116 Lot 2 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 1.10 · 95% CI 0.93 to 1.29V116 Lot 1/V116 Lot 2
  • V116 Lot 1 vs V116 Lot 3 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 1.03 · 95% CI 0.87 to 1.21V116 Lot 1/V116 Lot 3
  • V116 Lot 2 vs V116 Lot 3 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 0.94 · 95% CI 0.80 to 1.10V116 Lot 2/V116 Lot 3
  • V116 Lot 1 vs V116 Lot 2 · cDLA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 1.00 · 95% CI 0.85 to 1.17V116 Lot 1/V116 Lot 2
  • V116 Lot 1 vs V116 Lot 3 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 1.01 · 95% CI 0.86 to 1.19V116 Lot 1/V116 Lot 3
  • V116 Lot 2 vs V116 Lot 3 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 1.02 · 95% CI 0.87 to 1.19V116 Lot 2/V116 Lot 3
  • V116 Lot 1 vs V116 Lot 2 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 1.22 · 95% CI 1.00 to 1.48V116 Lot 1/V116 Lot 2
  • V116 Lot 1 vs V116 Lot 3 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 0.98 · 95% CI 0.80 to 1.19V116 Lot 1/V116 Lot 3
  • V116 Lot 2 vs V116 Lot 3 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 0.80 · 95% CI 0.66 to 0.97V116 Lot 2/V116 Lot 3
  • V116 Lot 1 vs V116 Lot 2 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 1.02 · 95% CI 0.88 to 1.18V116 Lot 1/V116 Lot 2
  • V116 Lot 1 vs V116 Lot 3 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 1.02 · 95% CI 0.88 to 1.18V116 Lot 1/V116 Lot 3
  • V116 Lot 2 vs V116 Lot 3 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 1.01 · 95% CI 0.87 to 1.16V116 Lot 2/V116 Lot 3
  • V116 Lot 1 vs V116 Lot 2 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 1.02 · 95% CI 0.87 to 1.20V116 Lot 1/V116 Lot 2
  • V116 Lot 1 vs V116 Lot 3 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 1.02 · 95% CI 0.87 to 1.20V116 Lot 1/V116 Lot 3
  • V116 Lot 2 vs V116 Lot 3 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 1.00 · 95% CI 0.85 to 1.17V116 Lot 2/V116 Lot 3
  • V116 Lot 1 vs V116 Lot 2 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 1.11 · 95% CI 0.93 to 1.33V116 Lot 1/V116 Lot 2
  • V116 Lot 1 vs V116 Lot 3 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 1.08 · 95% CI 0.90 to 1.29V116 Lot 1/V116 Lot 3
  • V116 Lot 2 vs V116 Lot 3 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 0.97 · 95% CI 0.81 to 1.16V116 Lot 2/V116 Lot 3
  • V116 Lot 1 vs V116 Lot 2 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 1.03 · 95% CI 0.91 to 1.17V116 Lot 1/V116 Lot 2
  • V116 Lot 1 vs V116 Lot 3 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 1.04 · 95% CI 0.91 to 1.18V116 Lot 1/V116 Lot 3
  • V116 Lot 2 vs V116 Lot 3 · cLDA model · p = <0.001 (Identical p-values for the lower and upper bounds.) · Gmt ratio: 1.01 · 95% CI 0.89 to 1.14V116 Lot 2/V116 Lot 3
SecondaryGMTs of Serotype-specific OPA for All Serotypes in V116 Following Vaccination: Combined Lots of V116 or PPSV23

Serotype-specific OPA titers for all serotypes in V116 following vaccination were determined using MOPA. Serotype-specific OPA GMTs and GMT ratios with 95% CI were calculated using a constrained longitudinal data analysis (cLDA) model. Per protocol, within-group CIs were not calculated.

Time frame:
Day 30
Reported as:
Geometric mean · Titers
GMTs of Serotype-specific OPA for All Serotypes in V116 Following Vaccination: Combined Lots of V116 or PPSV23
TitersV116 Combined Lots 1, 2 and 3PPSV23
Serotype 3316.5 (NA to NA)339.8 (NA to NA)
Serotype 6A6491.7 (NA to NA)1866.4 (NA to NA)
Serotype 7F6702.2 (NA to NA)5058.1 (NA to NA)
Serotype 83847.3 (NA to NA)4543.3 (NA to NA)
Serotype 9N18166.7 (NA to NA)19031.9 (NA to NA)
Serotype 10A7618.2 (NA to NA)5763.0 (NA to NA)
Serotype 11A6494.4 (NA to NA)3728.0 (NA to NA)
Serotype 12F7196.9 (NA to NA)5207.5 (NA to NA)
Serotype 15A10520.0 (NA to NA)2608.5 (NA to NA)
Serotype 15C11922.3 (NA to NA)4112.0 (NA to NA)
Serotype 16F9415.3 (NA to NA)2532.2 (NA to NA)
Serotype 17F17330.5 (NA to NA)10159.9 (NA to NA)
Serotype 19A3222.9 (NA to NA)3474.7 (NA to NA)
Serotype 20A16183.8 (NA to NA)10994.2 (NA to NA)
Serotype 22F11118.1 (NA to NA)8308.0 (NA to NA)
Serotype 23A8428.3 (NA to NA)1056.1 (NA to NA)
Serotype 23B2825.4 (NA to NA)119.1 (NA to NA)
Serotype 24F4892.9 (NA to NA)250.3 (NA to NA)
Serotype 318865.6 (NA to NA)654.5 (NA to NA)
Serotype 33F35684.3 (NA to NA)42515.6 (NA to NA)
Serotype 35B12798.6 (NA to NA)3452.1 (NA to NA)
Statistical analysis
  • V116 Combined Lots 1, 2 and 3 vs PPSV23 · Gmt ratio: 0.93 · 95% CI 0.84 to 1.03V116 Combined Lots/PPSV23
  • V116 Combined Lots 1, 2 and 3 vs PPSV23 · Gmt ratio: 3.48 · 95% CI 3.01 to 4.02V116 Combined Lots/PPSV23
  • V116 Combined Lots 1, 2 and 3 vs PPSV23 · Gmt ratio: 1.33 · 95% CI 1.18 to 1.49V116 Combined Lots/PPSV23
  • V116 Combined Lots 1, 2 and 3 vs PPSV23 · Gmt ratio: 0.85 · 95% CI 0.77 to 0.93V116 Combined Lots/PPSV23
  • V116 Combined Lots 1, 2 and 3 vs PPSV23 · Gmt ratio: 0.95 · 95% CI 0.85 to 1.08V116 Combined Lots/PPSV23
  • V116 Combined Lots 1, 2 and 3 vs PPSV23 · Gmt ratio: 1.32 · 95% CI 1.18 to 1.48V116 Combined Lots/PPSV23
  • V116 Combined Lots 1, 2 and 3 vs PPSV23 · Gmt ratio: 1.74 · 95% CI 1.56 to 1.95V116 Combined Lots/PPSV23
  • V116 Combined Lots 1, 2 and 3 vs PPSV23 · Gmt ratio: 1.38 · 95% CI 1.22 to 1.56V116 Combined Lots/PPSV23
  • V116 Combined Lots 1, 2 and 3 vs PPSV23 · Gmt ratio: 4.03 · 95% CI 3.56 to 4.56V116 Combined Lots/PPSV23
  • V116 Combined Lots 1, 2 and 3 vs PPSV23 · Gmt ratio: 2.90 · 95% CI 2.49 to 3.38V116 Combined Lots/PPSV23
  • V116 Combined Lots 1, 2 and 3 vs PPSV23 · Gmt ratio: 3.72 · 95% CI 3.32 to 4.17
  • V116 Combined Lots 1, 2 and 3 vs PPSV23 · Gmt ratio: 1.71 · 95% CI 1.53 to 1.91V116 Combined Lots/PPSV23
  • V116 Combined Lots 1, 2 and 3 vs PPSV23 · Gmt ratio: 0.93 · 95% CI 0.84 to 1.03V116 Combined Lots/PPSV23
  • V116 Combined Lots 1, 2 and 3 vs PPSV23 · Gmt ratio: 1.47 · 95% CI 1.30 to 1.67V116 Combined Lots/PPSV23
  • V116 Combined Lots 1, 2 and 3 vs PPSV23 · Gmt ratio: 1.34 · 95% CI 1.17 to 1.53V116 Combined Lots/PPSV23
  • V116 Combined Lots 1, 2 and 3 vs PPSV23 · Gmt ratio: 7.98 · 95% CI 6.84 to 9.31V116 Combined Lots/PPSV23
  • V116 Combined Lots 1, 2 and 3 vs PPSV23 · Gmt ratio: 23.72 · 95% CI 19.71 to 28.55V116 Combined Lots/PPSV23
  • V116 Combined Lots 1, 2 and 3 vs PPSV23 · Gmt ratio: 19.55 · 95% CI 16.70 to 22.88V116 Combined Lots/PPSV23
  • V116 Combined Lots 1, 2 and 3 vs PPSV23 · Gmt ratio: 13.55 · 95% CI 11.68 to 15.71V116 Combined Lots/PPSV23
  • V116 Combined Lots 1, 2 and 3 vs PPSV23 · Gmt ratio: 0.84 · 95% CI 0.73 to 0.97
  • V116 Combined Lots 1, 2 and 3 vs PPSV23 · Gmt ratio: 3.71 · 95% CI 3.36 to 4.09V116 Combined Lots/PPSV23
SecondaryGeometric Mean Concentrations (GMCs) of Serotype-specific Immunoglobulin G (IgG) for All Serotypes in V116 Following Vaccination With Separate V116 Lots

Serotype-specific IgG concentrations for all serotypes in V116 following vaccination were determined using pneumococcal electrochemiluminescence (PnECL). Serotype-specific pneumococcal IgG GMCs and GMC ratios with 95% confidence intervals were calculated using a cLDA model. Per protocol, within-group CIs were not calculated and the PPSV23 treatment group was not included as it was not analyzed with the individual lots of V116.

Time frame:
Day 30
Reported as:
Geometric mean · μg/mL
Geometric Mean Concentrations (GMCs) of Serotype-specific Immunoglobulin G (IgG) for All Serotypes in V116 Following Vaccination With Separate V116 Lots
μg/mLV116 Lot 1V116 Lot 2V116 Lot 3PPSV23
Serotype 30.83 (NA to NA)0.85 (NA to NA)0.87 (NA to NA)—
Serotype 6A5.94 (NA to NA)5.29 (NA to NA)5.84 (NA to NA)—
Serotype 7F5.13 (NA to NA)5.29 (NA to NA)4.99 (NA to NA)—
Serotype 810.32 (NA to NA)10.52 (NA to NA)10.42 (NA to NA)—
Serotype 9N5.37 (NA to NA)5.11 (NA to NA)6.03 (NA to NA)—
Serotype 10A9.63 (NA to NA)9.52 (NA to NA)9.97 (NA to NA)—
Serotype 11A6.33 (NA to NA)6.28 (NA to NA)6.21 (NA to NA)—
Serotype 12F1.65 (NA to NA)1.75 (NA to NA)1.65 (NA to NA)—
Serotype 15A13.63 (NA to NA)13.00 (NA to NA)14.20 (NA to NA)—
Serotype 15C14.32 (NA to NA)13.54 (NA to NA)13.85 (NA to NA)—
Serotype 16F1.77 (NA to NA)1.97 (NA to NA)1.96 (NA to NA)—
Serotype 17F14.05 (NA to NA)13.37 (NA to NA)13.14 (NA to NA)—
Serotype 19A7.70 (NA to NA)7.94 (NA to NA)8.51 (NA to NA)—
Serotype 20A13.54 (NA to NA)14.18 (NA to NA)14.09 (NA to NA)—
Serotype 22F7.02 (NA to NA)6.97 (NA to NA)6.99 (NA to NA)—
Serotype 23A4.26 (NA to NA)4.34 (NA to NA)4.34 (NA to NA)—
Serotype 23B6.77 (NA to NA)6.65 (NA to NA)7.39 (NA to NA)—
Serotype 24F4.32 (NA to NA)4.55 (NA to NA)4.34 (NA to NA)—
Serotype 313.47 (NA to NA)3.94 (NA to NA)3.47 (NA to NA)—
Serotype 33F8.03 (NA to NA)7.94 (NA to NA)8.00 (NA to NA)—
Serotype 35B11.84 (NA to NA)11.56 (NA to NA)11.94 (NA to NA)—
Statistical analysis
  • V116 Lot 1 vs V116 Lot 2 · Gmc ratio: 0.98 · 95% CI 0.88 to 1.09V116 Lot 1/V116 Lot 2
  • V116 Lot 1 vs V116 Lot 3 · Gmc ratio: 0.95 · 95% CI 0.85 to 1.05V116 Lot 1/V116 Lot 3
  • V116 Lot 2 vs V116 Lot 3 · Gmc ratio: 0.97 · 95% CI 0.87 to 1.08V116 Lot 2/V116 Lot 3
  • V116 Lot 1 vs V116 Lot 2 · Gmc ratio: 1.12 · 95% CI 0.95 to 1.32V116 Lot 1/V116 Lot 2
  • V116 Lot 1 vs V116 Lot 3 · Gmc ratio: 1.02 · 95% CI 0.86 to 1.20V116 Lot 1/V116 Lot 3
  • V116 Lot 2 vs V116 Lot 3 · Gmc ratio: 0.91 · 95% CI 0.77 to 1.07V116 Lot 2/V116 Lot 3
  • V116 Lot 1 vs V116 Lot 2 · Gmc ratio: 0.97 · 95% CI 0.85 to 1.11V116 Lot 1/V116 Lot 2
  • V116 Lot 1 vs V116 Lot 3 · Gmc ratio: 1.03 · 95% CI 0.90 to 1.18V116 Lot 1/V116 Lot 3
  • V116 Lot 2 vs V116 Lot 3 · Gmc ratio: 1.06 · 95% CI 0.93 to 1.21V116 Lot 2/V116 Lot 3
  • V116 Lot 1 vs V116 Lot 2 · Gmc ratio: 0.98 · 95% CI 0.86 to 1.12V116 Lot 1/V116 Lot 2
  • V116 Lot 1 vs V116 Lot 3 · Gmc ratio: 0.99 · 95% CI 0.87 to 1.13V116 Lot 1/V116 Lot 3
  • V116 Lot 2 vs V116 Lot 3 · Gmc ratio: 1.01 · 95% CI 0.89 to 1.15V116 Lot 2/V116 Lot 3
  • V116 Lot 1 vs V116 Lot 2 · Gmc ratio: 1.05 · 95% CI 0.91 to 1.21V116 Lot 1/V116 Lot 2
  • V116 Lot 1 vs V116 Lot 3 · Gmc ratio: 0.89 · 95% CI 0.77 to 1.03V116 Lot 1/V116 Lot 3
  • V116 Lot 2 vs V116 Lot 3 · Gmc ratio: 0.85 · 95% CI 0.74 to 0.98V116 Lot 2/V116 Lot 3
  • V116 Lot 1 vs V116 Lot 2 · Gmc ratio: 1.01 · 95% CI 0.87 to 1.18V116 Lot 1/V116 Lot 2
  • V116 Lot 1 vs V116 Lot 3 · Gmc ratio: 0.97 · 95% CI 0.83 to 1.13V116 Lot 1/V116 Lot 3
  • V116 Lot 2 vs V116 Lot 3 · Gmc ratio: 0.95 · 95% CI 0.82 to 1.11V116 Lot 2/V116 Lot 3
  • V116 Lot 1 vs V116 Lot 2 · Gmc ratio: 1.01 · 95% CI 0.90 to 1.14V116 Lot 1/V116 Lot 2
  • V116 Lot 1 vs V116 Lot 3 · Gmc ratio: 1.02 · 95% CI 0.91 to 1.15V116 Lot 1/V116 Lot 3
  • V116 Lot 2 vs V116 Lot 3 · Gmc ratio: 1.01 · 95% CI 0.90 to 1.14V116 Lot 2/V116 Lot 3
  • V116 Lot 1 vs V116 Lot 2 · Gmc ratio: 0.95 · 95% CI 0.80 to 1.12V116 Lot 1/V116 Lot 2
  • V116 Lot 1 vs V116 Lot 3 · Gmc ratio: 1.00 · 95% CI 0.84 to 1.18V116 Lot 1/V116 Lot 3
  • V116 Lot 2 vs V116 Lot 3 · Gmc ratio: 1.06 · 95% CI 0.89 to 1.25V116 Lot 2/V116 Lot 3
  • V116 Lot 1 vs V116 Lot 2 · Gmc ratio: 1.05 · 95% CI 0.91 to 1.21V116 Lot 1/V116 Lot 2
  • V116 Lot 1 vs V116 Lot 3 · Gmc ratio: 0.96 · 95% CI 0.83 to 1.11V116 Lot 1/V116 Lot 3
  • V116 Lot 2 vs V116 Lot 3 · Gmc ratio: 0.92 · 95% CI 0.80 to 1.05V116 Lot 2/V116 Lot 3
  • V116 Lot 1 vs V116 Lot 2 · Gmc ratio: 1.06 · 95% CI 0.91 to 1.23V116 Lot 1/V116 Lot 2
  • V116 Lot 1 vs V116 Lot 3 · Gmc ratio: 1.03 · 95% CI 0.89 to 1.20V116 Lot 1/V116 Lot 3
  • V116 Lot 2 vs V116 Lot 3 · Gmc ratio: 0.98 · 95% CI 0.84 to 1.14V116 Lot 2/V116 Lot 3
  • V116 Lot 1 vs V116 Lot 2 · Gmc ratio: 0.90 · 95% CI 0.78 to 1.03V116 Lot 1/V116 Lot 2
  • V116 Lot 1 vs V116 Lot 3 · Gmc ratio: 0.90 · 95% CI 0.78 to 1.04V116 Lot 1/V116 Lot 3
  • V116 Lot 2 vs V116 Lot 3 · Gmc ratio: 1.01 · 95% CI 0.88 to 1.15V116 Lot 2/V116 Lot 3
  • V116 Lot 1 vs V116 Lot 2 · Gmc ratio: 1.05 · 95% CI 0.91 to 1.21V116 Lot 1/V116 Lot 2
  • V116 Lot 1 vs V116 Lot 3 · Gmc ratio: 1.07 · 95% CI 0.93 to 1.23V116 Lot 1/V116 Lot 3
  • V116 Lot 2 vs V116 Lot 3 · Gmc ratio: 1.02 · 95% CI 0.88 to 1.17V116 Lot 2/V116 Lot 3
  • V116 Lot 1 vs V116 Lot 2 · Gmc ratio: 0.97 · 95% CI 0.85 to 1.11V116 Lot 1/V116 Lot 2
  • V116 Lot 1 vs V116 Lot 3 · Gmc ratio: 0.90 · 95% CI 0.79 to 1.04V116 Lot 1/V116 Lot 3
  • V116 Lot 2 vs V116 Lot 3 · Gmc ratio: 0.93 · 95% CI 0.82 to 1.07V116 Lot 2/V116 Lot 3
  • V116 Lot 1 vs V116 Lot 2 · Gmc ratio: 0.95 · 95% CI 0.83 to 1.10V116 Lot 1/V116 Lot 2
  • V116 Lot 1 vs V116 Lot 3 · Gmc ratio: 0.96 · 95% CI 0.84 to 1.10V116 Lot 1/V116 Lot 3
  • V116 Lot 2 vs V116 Lot 3 · Gmc ratio: 1.01 · 95% CI 0.88 to 1.16V116 Lot 2/V116 Lot 3
  • V116 Lot 1 vs V116 Lot 2 · Gmc ratio: 1.01 · 95% CI 0.87 to 1.16V116 Lot 1/V116 Lot 2
  • V116 Lot 1 vs V116 Lot 3 · Gmc ratio: 1.00 · 95% CI 0.87 to 1.16V116 Lot 1/V116 Lot 3
  • V116 Lot 2 vs V116 Lot 3 · Gmc ratio: 1.00 · 95% CI 0.86 to 1.15V116 Lot 2/V116 Lot 3
  • V116 Lot 1 vs V116 Lot 2 · Gmc ratio: 0.98 · 95% CI 0.84 to 1.16V116 Lot 1/V116 Lot 2
  • V116 Lot 1 vs V116 Lot 3 · Gmc ratio: 0.98 · 95% CI 0.83 to 1.15V116 Lot 1/V116 Lot 3
  • V116 Lot 2 vs V116 Lot 3 · Gmc ratio: 1.00 · 95% CI 0.85 to 1.17V116 Lot 2/V116 Lot 3
  • V116 Lot 1 vs V116 Lot 2 · Gmc ratio: 1.02 · 95% CI 0.87 to 1.18V116 Lot 1/V116 Lot 2
  • V116 Lot 1 vs V116 Lot 3 · Gmc ratio: 0.92 · 95% CI 0.79 to 1.07V116 Lot 1/V116 Lot 3
  • V116 Lot 2 vs V116 Lot 3 · Gmc ratio: 0.90 · 95% CI 0.77 to 1.05V116 Lot 2/V116 Lot 3
  • V116 Lot 1 vs V116 Lot 2 · Gmc ratio: 0.95 · 95% CI 0.80 to 1.13V116 Lot 1/V116 Lot 2
  • V116 Lot 1 vs V116 Lot 3 · Gmc ratio: 1.00 · 95% CI 0.84 to 1.19V116 Lot 1/V116 Lot 3
  • V116 Lot 2 vs V116 Lot 3 · Gmc ratio: 1.05 · 95% CI 0.88 to 1.25V116 Lot 2/V116 Lot 3
  • V116 Lot 1 vs V116 Lot 2 · Gmc ratio: 0.88 · 95% CI 0.77 to 1.00V116 Lot 1/V116 Lot 2
  • V116 Lot 1 vs V116 Lot 3 · Gmc ratio: 1.00 · 95% CI 0.88 to 1.14V116 Lot 1/V116 Lot 3
  • V116 Lot 2 vs V116 Lot 3 · Gmc ratio: 1.14 · 95% CI 1.00 to 1.30V116 Lot 2/V116 Lot 3
  • V116 Lot 1 vs V116 Lot 2 · Gmc ratio: 1.01 · 95% CI 0.89 to 1.16V116 Lot 1/V116 Lot 2
  • V116 Lot 1 vs V116 Lot 3 · Gmc ratio: 1.00 · 95% CI 0.88 to 1.15V116 Lot 1/V116 Lot 3
  • V116 Lot 2 vs V116 Lot 3 · Gmc ratio: 0.99 · 95% CI 0.87 to 1.13V116 Lot 2/V116 Lot 3
  • V116 Lot 1 vs V116 Lot 2 · Gmc ratio: 1.02 · 95% CI 0.90 to 1.17V116 Lot 1/V116 Lot 2
  • V116 Lot 1 vs V116 Lot 3 · Gmc ratio: 0.99 · 95% CI 0.87 to 1.13V116 Lot 1/V116 Lot 3
  • V116 Lot 2 vs V116 Lot 3 · Gmc ratio: 0.97 · 95% CI 0.85 to 1.10V116 Lot 2/V116 Lot 3
SecondaryGMCs of Serotype-specific IgG for All Serotypes in V116 Following Vaccination: Combined Lots of V116 or PPSV23

Serotype-specific IgG concentrations for all serotypes in V116 following vaccination were determined using PnECL. Serotype-specific pneumococcal IgG GMCs and GMC ratios with 95% confidence intervals were calculated using a cLDA model. Per protocol, within-group CIs were not calculated.

Time frame:
Day 30
Reported as:
Geometric mean · μg/mL
GMCs of Serotype-specific IgG for All Serotypes in V116 Following Vaccination: Combined Lots of V116 or PPSV23
μg/mLV116 Combined Lots 1, 2, and 3PPSV23
Serotype 30.85 (NA to NA)0.77 (NA to NA)
Serotype 6A5.67 (NA to NA)1.45 (NA to NA)
Serotype 7F5.19 (NA to NA)3.36 (NA to NA)
Serotype 810.34 (NA to NA)12.85 (NA to NA)
Serotype 9N5.51 (NA to NA)5.41 (NA to NA)
Serotype 10A9.58 (NA to NA)6.52 (NA to NA)
Serotype 11A6.29 (NA to NA)4.55 (NA to NA)
Serotype 12F1.69 (NA to NA)1.20 (NA to NA)
Serotype 15A13.55 (NA to NA)1.99 (NA to NA)
Serotype 15C13.90 (NA to NA)4.29 (NA to NA)
Serotype 16F1.91 (NA to NA)0.30 (NA to NA)
Serotype 17F13.46 (NA to NA)7.28 (NA to NA)
Serotype 19A8.01 (NA to NA)7.29 (NA to NA)
Serotype 20A13.82 (NA to NA)9.03 (NA to NA)
Serotype 22F7.04 (NA to NA)5.34 (NA to NA)
Serotype 23A4.29 (NA to NA)0.53 (NA to NA)
Serotype 23B6.96 (NA to NA)1.21 (NA to NA)
Serotype 24F4.44 (NA to NA)0.31 (NA to NA)
Serotype 313.62 (NA to NA)0.38 (NA to NA)
Serotype 33F8.00 (NA to NA)9.82 (NA to NA)
Serotype 35B11.71 (NA to NA)1.66 (NA to NA)
Statistical analysis
  • V116 Combined Lots 1, 2, and 3 vs PPSV23 · Gmc ratio: 1.10 · 95% CI 1.01 to 1.21V116 Combined Lots/PPSV23
  • V116 Combined Lots 1, 2, and 3 vs PPSV23 · Gmc ratio: 3.91 · 95% CI 3.43 to 4.45V116 Combined Lots/PPSV23
  • V116 Combined Lots 1, 2, and 3 vs PPSV23 · Gmc ratio: 1.54 · 95% CI 1.38 to 1.72V116 Combined Lots/PPSV23
  • V116 Combined Lots 1, 2, and 3 vs PPSV23 · Gmc ratio: 0.81 · 95% CI 0.73 to 0.89V116 Combined Lots/PPSV23
  • V116 Combined Lots 1, 2, and 3 vs PPSV23 · Gmc ratio: 1.02 · 95% CI 0.91 to 1.14V116 Combined Lots/PPSV23
  • V116 Combined Lots 1, 2, and 3 vs PPSV23 · Gmc ratio: 1.47 · 95% CI 1.30 to 1.66V116 Combined Lots/PPSV23
  • V116 Combined Lots 1, 2, and 3 vs PPSV23 · Gmc ratio: 1.38 · 95% CI 1.26 to 1.52V116 Combined Lots/PPSV23
  • V116 Combined Lots 1, 2, and 3 vs PPSV23 · Gmc ratio: 1.41 · 95% CI 1.23 to 1.62V116 Combined Lots/PPSV23
  • V116 Combined Lots 1, 2, and 3 vs PPSV23 · Gmc ratio: 6.82 · 95% CI 6.08 to 7.65V116 Combined Lots/PPSV23
  • V116 Combined Lots 1, 2, and 3 vs PPSV23 · Gmc ratio: 3.24 · 95% CI 2.86 to 3.67V116 Combined Lots/PPSV23
  • V116 Combined Lots 1, 2, and 3 vs PPSV23 · Gmc ratio: 6.48 · 95% CI 5.83 to 7.19V116 Combined Lots/PPSV23
  • V116 Combined Lots 1, 2, and 3 vs PPSV23 · Gmc ratio: 1.85 · 95% CI 1.66 to 2.07V116 Combined Lots/PPSV23
  • V116 Combined Lots 1, 2, and 3 vs PPSV23 · Gmc ratio: 1.10 · 95% CI 0.98 to 1.22V116 Combined Lots/PPSV23
  • V116 Combined Lots 1, 2, and 3 vs PPSV23 · Gmc ratio: 1.53 · 95% CI 1.37 to 1.71V116 Combined Lots/PPSV23
  • V116 Combined Lots 1, 2, and 3 vs PPSV23 · Gmc ratio: 1.32 · 95% CI 1.17 to 1.49V116 Combined Lots/PPSV23
  • V116 Combined Lots 1, 2, and 3 vs PPSV23 · Gmc ratio: 8.14 · 95% CI 7.19 to 9.23V116 Combined Lots/PPSV23
  • V116 Combined Lots 1, 2, and 3 vs PPSV23 · Gmc ratio: 5.74 · 95% CI 5.08 to 6.48V116 Combined Lots/PPSV23
  • V116 Combined Lots 1, 2, and 3 vs PPSV23 · Gmc ratio: 14.47 · 95% CI 12.77 to 16.40V116 Combined Lots/PPSV23
  • V116 Combined Lots 1, 2, and 3 vs PPSV23 · Gmc ratio: 9.55 · 95% CI 8.61 to 10.59V116 Combined Lots/PPSV23
  • V116 Combined Lots 1, 2, and 3 vs PPSV23 · Gmc ratio: 0.81 · 95% CI 0.73 to 0.91V116 Combined Lots/PPSV23
  • V116 Combined Lots 1, 2, and 3 vs PPSV23 · Gmc ratio: 7.06 · 95% CI 6.41 to 7.77V116 Combined Lots/PPSV23
SecondaryGeometric Mean Fold Rise (GMFR) in Serotype-specific OPA for All Serotypes in V116 Following Vaccination With Separate V116 Lots

Serotype-specific OPA GMFR for all serotypes in V116 following vaccination were determined using MOPA. The GMFR of each pneumococcal serotype was calculated as Day 30 GMT/Day 1 GMT. The 95% CIs were calculated based on based on the t-distribution. Per protocol, the PPSV23 treatment group was not included as it was not analyzed with the individual lots of V116.

Time frame:
Baseline (Day 1) and Day 30
Reported as:
Geometric mean · Ratio
Geometric Mean Fold Rise (GMFR) in Serotype-specific OPA for All Serotypes in V116 Following Vaccination With Separate V116 Lots
RatioV116 Lot 1V116 Lot 2V116 Lot 3PPSV23
Serotype 38.2 (7.2 to 9.4)8.1 (7.2 to 9.1)8.2 (7.3 to 9.3)—
Serotype 6A46.8 (38.5 to 56.8)37.8 (31.1 to 45.9)35.8 (29.7 to 43.2)—
Serotype 7F17.6 (14.6 to 21.2)14.2 (11.8 to 17.0)14.8 (12.4 to 17.6)—
Serotype 817.6 (14.7 to 21.1)16.2 (13.6 to 19.2)15.4 (12.9 to 18.5)—
Serotype 9N10.1 (8.8 to 11.7)10.4 (9.0 to 12.0)10.5 (9.0 to 12.2)—
Serotype 10A14.1 (11.8 to 16.7)15.2 (12.8 to 18.0)15.9 (13.3 to 18.9)—
Serotype 11A11.5 (9.5 to 14.0)11.3 (9.3 to 13.8)9.3 (7.8 to 11.1)—
Serotype 12F173.7 (144.8 to 208.5)152.0 (127.5 to 181.2)194.1 (162.5 to 231.7)—
Serotype 15A9.3 (7.8 to 11.2)8.8 (7.5 to 10.5)9.5 (7.9 to 11.3)—
Serotype 15C86.0 (68.7 to 107.8)78.8 (64.0 to 97.0)63.8 (51.2 to 79.5)—
Serotype 16F7.1 (6.2 to 8.2)7.6 (6.6 to 8.8)6.9 (6.2 to 7.8)—
Serotype 17F17.8 (15.3 to 20.9)18.5 (15.8 to 21.6)16.9 (14.4 to 19.8)—
Serotype 19A8.9 (7.7 to 10.3)8.5 (7.4 to 9.9)8.9 (7.8 to 10.3)—
Serotype 20A10.6 (9.1 to 12.3)11.7 (10.2 to 13.4)9.5 (8.3 to 10.8)—
Serotype 22F20.0 (16.1 to 24.7)15.4 (12.6 to 18.8)18.1 (14.9 to 22.0)—
Serotype 23A30.9 (24.8 to 38.4)27.7 (22.6 to 34.1)30.0 (24.5 to 36.7)—
Serotype 23B104.1 (85.2 to 127.2)91.0 (74.5 to 111.2)106.0 (87.2 to 128.8)—
Serotype 24F27.0 (22.2 to 32.9)24.0 (19.6 to 29.2)25.4 (20.8 to 31.0)—
Serotype 3125.1 (20.3 to 31.2)25.7 (20.9 to 31.6)21.2 (17.2 to 26.1)—
Serotype 33F13.1 (11.2 to 15.2)12.5 (10.7 to 14.5)12.3 (10.6 to 14.2)—
Serotype 35B4.6 (4.1 to 5.2)5.0 (4.4 to 5.7)4.7 (4.1 to 5.3)—
SecondaryPercentage of Participants With ≥4-fold Rise in Serotype-specific OPA for All Serotypes in V116 Following Vaccination With Separate V116 Lots

Serotype-specific OPA titer were determined using MOPA. The percentage of participants with a ≥4-fold rise in serotype-specific OPA for all serotypes in V116 following vaccination were reported. The 95% CIs were calculated based on the exact binomial method proposed by Clopper and Pearson. Per protocol, the PPSV23 treatment group was not included as it was not analyzed with the individual lots of V116.

Time frame:
Baseline (Day 1) and Day 30
Reported as:
Number · Percentage of Participants
Percentage of Participants With ≥4-fold Rise in Serotype-specific OPA for All Serotypes in V116 Following Vaccination With Separate V116 Lots
Percentage of ParticipantsV116 Lot 1V116 Lot 2V116 Lot 3PPSV23
Serotype 370.7 (66.1 to 75.1)71.0 (66.4 to 75.2)70.6 (66.1 to 74.9)—
Serotype 6A87.2 (83.3 to 90.4)86.5 (82.7 to 89.7)85.6 (81.8 to 88.9)—
Serotype 7F73.5 (69.1 to 77.6)69.7 (65.1 to 73.9)71.7 (67.2 to 75.9)—
Serotype 872.7 (68.3 to 76.7)75.9 (71.7 to 79.7)70.4 (66.0 to 74.5)—
Serotype 9N69.6 (65.1 to 73.9)70.4 (65.9 to 74.6)72.1 (67.6 to 76.3)—
Serotype 10A70.6 (66.1 to 74.9)75.1 (70.8 to 79.0)73.8 (69.5 to 77.8)—
Serotype 11A64.3 (59.5 to 68.8)66.0 (61.3 to 70.4)61.3 (56.7 to 65.9)—
Serotype 12F94.5 (91.9 to 96.4)94.5 (92.0 to 96.4)95.6 (93.2 to 97.3)—
Serotype 15A66.9 (61.3 to 72.1)66.2 (60.7 to 71.3)67.5 (62.1 to 72.6)—
Serotype 15C87.5 (83.8 to 90.6)90.3 (87.0 to 93.0)88.3 (84.7 to 91.3)—
Serotype 16F66.0 (61.0 to 70.7)63.7 (58.8 to 68.4)62.5 (57.6 to 67.3)—
Serotype 17F82.0 (78.1 to 85.5)81.4 (77.5 to 84.9)80.8 (76.9 to 84.3)—
Serotype 19A65.2 (60.6 to 69.7)65.0 (60.4 to 69.3)66.2 (61.8 to 70.5)—
Serotype 20A72.3 (67.5 to 76.8)77.8 (73.4 to 81.8)72.7 (68.1 to 77.0)—
Serotype 22F76.3 (71.9 to 80.3)73.3 (68.7 to 77.5)78.4 (74.2 to 82.3)—
Serotype 23A79.7 (75.0 to 83.8)79.4 (74.9 to 83.4)82.1 (77.7 to 85.9)—
Serotype 23B91.4 (88.3 to 93.8)89.3 (86.0 to 92.0)90.3 (87.2 to 92.9)—
Serotype 24F78.9 (74.4 to 82.8)78.2 (73.8 to 82.2)76.7 (72.2 to 80.7)—
Serotype 3178.3 (73.9 to 82.4)79.1 (74.8 to 82.9)77.6 (73.2 to 81.6)—
Serotype 33F75.3 (70.7 to 79.5)73.2 (68.7 to 77.5)75.1 (70.7 to 79.1)—
Serotype 35B52.9 (48.0 to 57.7)49.5 (44.7 to 54.3)48.5 (43.8 to 53.3)—
SecondaryGMFR in Serotype-specific IgG for All Serotypes in V116 Following Vaccination With Separate V116 Lots

Serotype-specific IgG GMFR for all serotypes in V116 following vaccination were determined using PnECL. The GMFR for each pneumococcal IgG serotype was calculated as Day 30 GMC/Day 1 GMC. The 95% CIs were calculated based on the t-distribution. Per protocol, the PPSV23 treatment group was not included as it was not analyzed with the individual lots of V116.

Time frame:
Baseline (Day 1) and Day 30
Reported as:
Geometric mean · Ratio
GMFR in Serotype-specific IgG for All Serotypes in V116 Following Vaccination With Separate V116 Lots
RatioV116 Lot 1V116 Lot 2V116 Lot 3PPSV23
Serotype 34.4 (4.0 to 4.8)4.7 (4.3 to 5.2)4.6 (4.1 to 5.0)—
Serotype 6A21.2 (18.7 to 24.1)18.8 (16.6 to 21.5)21.0 (18.7 to 23.7)—
Serotype 7F13.7 (12.3 to 15.2)13.4 (12.1 to 14.8)12.6 (11.3 to 14.0)—
Serotype 814.3 (12.7 to 16.2)15.2 (13.5 to 17.0)14.5 (12.8 to 16.4)—
Serotype 9N15.9 (14.3 to 17.8)15.3 (13.6 to 17.3)17.1 (15.2 to 19.3)—
Serotype 10A15.0 (13.4 to 16.8)15.2 (13.5 to 17.1)15.7 (14.0 to 17.6)—
Serotype 11A7.2 (6.5 to 8.0)7.2 (6.5 to 8.0)7.0 (6.3 to 7.8)—
Serotype 12F16.3 (14.4 to 18.4)17.1 (15.1 to 19.3)15.8 (14.1 to 17.8)—
Serotype 15A23.1 (20.6 to 25.9)22.8 (20.4 to 25.5)23.4 (20.9 to 26.3)—
Serotype 15C28.5 (25.3 to 32.2)27.8 (24.7 to 31.3)27.3 (24.2 to 30.9)—
Serotype 16F8.4 (7.6 to 9.3)8.8 (7.9 to 9.9)9.1 (8.2 to 10.1)—
Serotype 17F23.5 (21.0 to 26.3)23.1 (20.6 to 25.9)21.5 (19.2 to 24.1)—
Serotype 19A5.5 (4.9 to 6.1)5.8 (5.2 to 6.4)6.0 (5.4 to 6.7)—
Serotype 20A9.2 (8.3 to 10.3)9.8 (8.8 to 10.9)9.8 (8.8 to 10.9)—
Serotype 22F20.4 (17.9 to 23.3)19.1 (16.6 to 22.0)19.4 (17.0 to 22.2)—
Serotype 23A20.3 (18.0 to 22.8)20.1 (17.9 to 22.5)20.3 (18.0 to 22.9)—
Serotype 23B13.9 (12.2 to 15.7)14.0 (12.2 to 16.0)15.0 (13.2 to 17.1)—
Serotype 24F14.7 (13.0 to 16.6)15.4 (13.6 to 17.5)14.6 (12.9 to 16.6)—
Serotype 3113.6 (12.3 to 15.0)15.7 (14.1 to 17.5)13.0 (11.7 to 14.5)—
Serotype 33F8.8 (7.9 to 9.8)9.1 (8.2 to 10.1)9.1 (8.2 to 10.0)—
Serotype 35B7.3 (6.5 to 8.1)7.3 (6.6 to 8.1)7.2 (6.5 to 8.0)—
SecondaryPercentage of Participants With ≥4-fold Rise in Serotype-specific IgG for All Serotypes in V116 Following Vaccination With Separate V116 Lots

Serotype-specific IgG concentrations were determined using PnECL. The percentage of participants with a ≥4-fold rise in serotype-specific IgG for all serotypes in V116 were reported. The 95% CIs were calculated based on the exact binomial method proposed by Clopper and Pearson. Per protocol, the PPSV23 treatment group was not included as it was not analyzed with the individual lots of V116.

Time frame:
Baseline (Day 1) and Day 30
Reported as:
Number · Percentage of Participants
Percentage of Participants With ≥4-fold Rise in Serotype-specific IgG for All Serotypes in V116 Following Vaccination With Separate V116 Lots
Percentage of ParticipantsV116 Lot 1V116 Lot 2V116 Lot 3PPSV23
Serotype 351.8 (47.3 to 56.3)54.4 (49.9 to 58.8)52.0 (47.5 to 56.4)—
Serotype 6A87.8 (84.6 to 90.6)85.3 (81.9 to 88.2)89.3 (86.3 to 91.9)—
Serotype 7F83.2 (79.6 to 86.4)84.1 (80.6 to 87.2)82.6 (79.0 to 85.8)—
Serotype 880.5 (76.8 to 83.9)82.7 (79.1 to 85.9)81.4 (77.8 to 84.7)—
Serotype 9N86.0 (82.6 to 88.9)84.1 (80.6 to 87.2)82.8 (79.2 to 86.0)—
Serotype 10A82.8 (79.2 to 86.0)82.4 (78.8 to 85.7)83.4 (79.9 to 86.5)—
Serotype 11A67.4 (63.1 to 71.5)67.3 (63.0 to 71.4)63.8 (59.5 to 68.0)—
Serotype 12F83.8 (80.3 to 86.9)85.1 (81.6 to 88.1)84.4 (80.9 to 87.4)—
Serotype 15A91.1 (88.2 to 93.4)89.2 (86.2 to 91.8)90.3 (87.4 to 92.7)—
Serotype 15C90.9 (88.0 to 93.3)90.8 (88.0 to 93.2)90.1 (87.2 to 92.6)—
Serotype 16F73.2 (69.1 to 77.1)72.5 (68.4 to 76.4)74.7 (70.6 to 78.4)—
Serotype 17F90.3 (87.3 to 92.7)91.0 (88.2 to 93.4)87.7 (84.6 to 90.5)—
Serotype 19A58.5 (54.0 to 62.9)58.6 (54.1 to 62.9)59.3 (54.9 to 63.6)—
Serotype 20A72.9 (68.7 to 76.7)76.1 (72.1 to 79.8)74.8 (70.8 to 78.5)—
Serotype 22F84.2 (80.7 to 87.3)79.5 (75.7 to 82.9)84.2 (80.7 to 87.3)—
Serotype 23A89.0 (85.9 to 91.6)88.8 (85.8 to 91.5)86.3 (83.0 to 89.2)—
Serotype 23B77.6 (73.7 to 81.2)77.1 (73.2 to 80.7)78.6 (74.8 to 82.1)—
Serotype 24F81.1 (77.4 to 84.5)80.9 (77.2 to 84.2)79.6 (75.9 to 83.1)—
Serotype 3185.8 (82.4 to 88.7)84.3 (80.8 to 87.3)82.4 (78.8 to 85.6)—
Serotype 33F73.5 (69.4 to 77.3)71.7 (67.6 to 75.6)73.7 (69.6 to 77.5)—
Serotype 35B67.8 (63.5 to 71.9)66.7 (62.4 to 70.8)64.2 (59.8 to 68.3)—
SecondaryGMTs of Serotype-specific OPA for Cross-reactive Serotypes Following Vaccination With Separate V116 Lots

Serotype-specific OPA titers for cross-reactive serotypes (6A, 6C, 15B, and 15C) were determined using MOPA. The 95% CIs for serotype-specific OPA GMTs were calculated based on based on the t-distribution. Per protocol, the PPSV23 treatment group was not included as it was not analyzed with the individual lots of V116.

Time frame:
Day 30
Reported as:
Geometric mean · Titers
GMTs of Serotype-specific OPA for Cross-reactive Serotypes Following Vaccination With Separate V116 Lots
TitersV116 Lot 1V116 Lot 2V116 Lot 3PPSV23
Serotype 6A6849.6 (6120.8 to 7665.0)6009.2 (5348.8 to 6751.0)6724.3 (5967.6 to 7577.0)—
Serotype 6C3972.7 (3501.8 to 4506.9)3421.5 (3006.5 to 3893.8)3750.9 (3298.0 to 4265.9)—
Serotype 15B11799.5 (10317.9 to 13493.8)10062.4 (8838.3 to 11456.1)11139.5 (9619.7 to 12899.4)—
Serotype 15C13079.8 (11543.5 to 14820.6)11332.5 (9905.9 to 12964.7)11290.9 (9805.6 to 13001.2)—

Adverse events

Collected over Non-serious adverse events were collected up to 30 days postvaccination. Serious adverse events and all-cause mortality were reported throughout the duration of the study, up to 194 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
V116 Lot 10/541 (0%)8/539 (1.5%)428/539 (79.4%)
V116 Lot 20/540 (0%)5/536 (0.9%)415/536 (77.4%)
V116 Lot 30/541 (0%)1/541 (0.2%)421/541 (77.8%)
PPSV231/540 (0.2%)6/541 (1.1%)388/541 (71.7%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventV116 Lot 1V116 Lot 2V116 Lot 3PPSV23
Chest discomfortGeneral disorders0/5391/5360/5410/541
Endometrial cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/5391/5360/5410/541
Bipolar disorderPsychiatric disorders0/5391/5361/5410/541
DepressionPsychiatric disorders0/5391/5360/5410/541
Major depressionPsychiatric disorders0/5391/5360/5410/541
Intestinal perforationGastrointestinal disorders1/5390/5360/5410/541
Abdominal abscessInfections and infestations1/5390/5360/5410/541
ConcussionInjury, poisoning and procedural complications1/5390/5360/5410/541
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/5390/5360/5410/541
Clear cell renal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/5390/5360/5410/541
Most frequent other events
Most frequent other events
EventV116 Lot 1V116 Lot 2V116 Lot 3PPSV23
Injection site painGeneral disorders393/539391/536400/541328/541
FatigueGeneral disorders206/539184/536187/541184/541
HeadacheNervous system disorders165/539154/536154/541131/541
MyalgiaMusculoskeletal and connective tissue disorders98/53975/53695/54149/541
Injection site swellingGeneral disorders68/53982/53664/54141/541
Injection site erythemaGeneral disorders74/53979/53671/54141/541

Baseline characteristics

Age, Continuous
Age, Continuous(Years)V116 Lot 1V116 Lot 2V116 Lot 3PPSV23Total
Mean34.8 ± 9.334.8 ± 9.234.3 ± 9.334.4 ± 9.234.6 ± 9.3
Sex: Female, Male
Sex: Female, Male(Participants)V116 Lot 1V116 Lot 2V116 Lot 3PPSV23Total
Female3053213113101247
Male236219230230915
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)V116 Lot 1V116 Lot 2V116 Lot 3PPSV23Total
Hispanic or Latino98104113107422
Not Hispanic or Latino4404344204301724
Unknown or Not Reported328316
Race (NIH/OMB)
Race (NIH/OMB)(Participants)V116 Lot 1V116 Lot 2V116 Lot 3PPSV23Total
American Indian or Alaska Native624416
Asian9126835
Native Hawaiian or Other Pacific Islander21014
Black or African American49435548195
White4584584584531827
More than one race1624162682
Unknown or Not Reported10203
08

Study locations

72 sites
  • Desert Clinical Research/ CCT Research ( Site 0019)
    Mesa, Arizona 85213, United States
  • Fiel Family and Sports Medicine, PC/CCT Research ( Site 0008)
    Tempe, Arizona 85283, United States
  • Baptist Health Center For Clinical Research ( Site 0015)
    Little Rock, Arkansas 72205, United States
  • Valley Clinical Trials, Inc. ( Site 0023)
    Northridge, California 91325, United States
  • Artemis Institute for Clinical Research ( Site 0027)
    San Diego, California 92103, United States
  • Millennium Clinical Trials ( Site 0004)
    Simi Valley, California 93065, United States
  • Diablo Clinical Research, Inc. ( Site 0022)
    Walnut Creek, California 94598, United States
  • Lynn Institute of Denver ( Site 0003)
    Aurora, Colorado 80012, United States
  • Indago Research & Health Center, Inc ( Site 0011)
    Hialeah, Florida 33012, United States
  • L&C Professional Medical Research Institute ( Site 0012)
    Miami, Florida 33144, United States
  • Headlands Research Orlando ( Site 0017)
    Orlando, Florida 32819, United States
  • Clinical Research Trials of Florida ( Site 0001)
    Tampa, Florida 33607, United States
  • Clinical Research Prime Rexburg ( Site 0040)
    Rexburg, Idaho 83440, United States
  • Healthcare Research Network - Chicago ( Site 0006)
    Flossmoor, Illinois 60422, United States
  • Kentucky Pediatric/ Adult Research ( Site 0036)
    Bardstown, Kentucky 40004, United States
  • Alliance for Multispecialty Research, LLC ( Site 0031)
    Kansas City, Missouri 64114, United States
  • Methodist Physicians Clinic/CCT Research ( Site 0029)
    Fremont, Nebraska 68025, United States
  • Healor Primary Care / CCT Research ( Site 0028)
    Las Vegas, Nevada 89102, United States
  • Axces Research ( Site 0034)
    Santa Fe, New Mexico 87505, United States
  • Rochester Clinical Research, Inc. ( Site 0033)
    Rochester, New York 14609, United States
  • M3 Wake Research Associates ( Site 0035)
    Raleigh, North Carolina 27612, United States
  • Lynn Health Science Institute ( Site 0014)
    Oklahoma City, Oklahoma 73112, United States
  • Velocity Clinical Research, Providence ( Site 0018)
    East Greenwich, Rhode Island 02818, United States
  • Velocity Clinical Research, Greenville ( Site 0021)
    Greenville, South Carolina 29615, United States
  • Clinical Research Associates Inc ( Site 0039)
    Nashville, Tennessee 37203, United States
  • DCOL Center for Clinical Research ( Site 0025)
    Longview, Texas 75605, United States
  • IMA Clinical Research San Antonio ( Site 0020)
    San Antonio, Texas 78229, United States
  • Dynamed Clinical Research, LP d/b/a DM Clinical Research ( Site 0016)
    Tomball, Texas 77375, United States
  • Charlottesville Medical Research ( Site 0013)
    Charlottesville, Virginia 22911, United States
  • Health Research of Hampton Roads, Inc. ( Site 0002)
    Newport News, Virginia 23606, United States
  • Medizinische Universität Graz-Klinische Abteilung für Pulmonologie ( Site 0304)
    Graz, Steiermark 8036, Austria
  • Medizinische Universitaet Innsbruck ( Site 0301)
    Innsbruck, Tirol 6020, Austria
  • Tropeninstitut Wien 1060 ( Site 0300)
    Vienna, Wien 1060, Austria
  • Medizinische Universität Wien ( Site 0302)
    Wien, 1090, Austria
  • Colchester Research Group ( Site 0202)
    Truro, Nova Scotia B2N 1L2, Canada
  • Hamilton Medical Research Group ( Site 0208)
    Hamilton, Ontario L8M 1K7, Canada
  • Milestone Research Inc. ( Site 0201)
    London, Ontario N5W 6A2, Canada
  • Manna Research Toronto ( Site 0209)
    Toronto, Ontario M9W 4L6, Canada
  • Manna Research Mirabel ( Site 0207)
    Mirabel, Quebec J7J 2K8, Canada
  • Manna Research Montreal ( Site 0203)
    Pointe-Claire, Quebec H9R 4S3, Canada
  • Q&T Research Sherbrooke Inc. ( Site 0204)
    Sherbrooke, Quebec J1J 2G2, Canada
  • Diex Recherche Trois-Rivieres ( Site 0206)
    Trois-Rivieres, Quebec G9A 4P3, Canada
  • Sanos Clinic-Sanos Clinic ( Site 0402)
    Herlev, Hovedstaden 2730, Denmark
  • Danske Lægers Vaccinations Service - Søborg ( Site 0404)
    Soborg, Hovedstaden 2860, Denmark
  • Danske Lægers Vaccinations Service - Århus ( Site 0403)
    Aarhus, Midtjylland 8000, Denmark
  • Sanos Clinic - Nordjylland ( Site 0401)
    Aalborg, Nordjylland 9362, Denmark
  • Sanos Clinic - Syddanmark ( Site 0400)
    Vejle, Syddanmark 7100, Denmark
  • FVR, Oulun rokotetutkimusklinikka ( Site 0501)
    Oulu, Pohjois-Pohjanmaa 90220, Finland
  • FVR, Porin rokotetutkimusklinikka ( Site 0508)
    Pori, Satakunta 28100, Finland
  • FVR, Seinäjoen rokotetutkimusklinikka ( Site 0504)
    Seinajoki, Sodra Osterbotten 60100, Finland
  • FVR, Espoon rokotetutkimusklinikka ( Site 0509)
    Espoo, Uusimaa 02230, Finland
  • FVR, Etelä-Helsingin rokotetutkimusklinikka ( Site 0503)
    Helsinki, Uusimaa 00100, Finland
  • Helsinki East Vaccine Research Clinic ( Site 0502)
    Helsinki, Uusimaa 00930, Finland
  • FVR, Turun rokotetutkimusklinikka ( Site 0500)
    Turku, Varsinais-Suomi 20520, Finland
  • Rambam Health Care Campus ( Site 0603)
    Haifa, 3109601, Israel
  • Maccabi Healthcare Services ( Site 0606)
    Jerusalem, 71713, Israel
  • Hadassah Medical Center ( Site 0600)
    Jerusalem, 9112001, Israel
  • Meir Medical Center ( Site 0601)
    Kfar Saba, 4428164, Israel
  • Sheba Medical Center-Early Phase Clinical Trials Unit ( Site 0604)
    Ramat Gan, 5265601, Israel
  • Clalit Health Services - Sakhnin Community Clinic-Research Unit ( Site 0602)
    Sakhnin, 3081000, Israel
  • IN VIVO ( Site 0711)
    Bydgoszcz, Kujawsko-pomorskie 85-048, Poland
  • Centrum Medyczne Pratia Bydgoszcz-Centrum Medyczne Pratia Bydgoszcz ( Site 0709)
    Bydgoszcz, Kujawsko-pomorskie 85-796, Poland
  • MICS Centrum Medyczne Torun ( Site 0706)
    Torun, Kujawsko-pomorskie 87-100, Poland
  • Clinmedica OMC ( Site 0701)
    Skierniewice, Lodzkie 96-100, Poland
  • Alergotest s.c Specjalistyczne Centrum Medyczne ( Site 0703)
    Lublin, Lubelskie 20-095, Poland
  • Centrum Medyczne Medyk ( Site 0704)
    Rzeszow, Podkarpackie 35-055, Poland
  • EBA CENTELLES ( Site 0800)
    Centelles, Cataluna 08500, Spain
  • HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID-Respiratory ( Site 0808)
    Pozuelo de Alarcon, Madrid 28223, Spain
  • Fundación Oftalmologica del Mediterraneo-Vaccine Research ( Site 0818)
    València, Valenciana, Comunitat 46015, Spain
  • Centre d'Atenció Primària Vallcarca - Sant Gervasi ( Site 0801)
    Barcelona, 08023, Spain
  • EAP Sardenya ( Site 0802)
    Barcelona, 08025, Spain
  • Hospital La Princesa-Clinical Pharmacology ( Site 0815)
    Madrid, 28006, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in May 2023, 9 months.

Results were first posted in May 2024, 11 months after primary completion.

Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 9 months is below that.

Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2022
First posted
Jul 19, 2022
StartActual
Aug 12, 2022
Primary completionActual
May 25, 2023
CompletionActual
May 25, 2023
Results first posted
May 24, 2024
Last update
Sep 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05464420
Responsible party
Sponsor
First posted
Jul 19, 2022
Start date
Aug 12, 2022
Primary completion
May 25, 2023
Completion
May 25, 2023
Results posted
May 24, 2024
Last update
Sep 24, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pneumococcal 21-Valent Conjugate Vaccine

Start the discussion